- Home
- FHI vs PTGX Comparison
FHI vs PTGX Comparison
Compare FHI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHI
- PTGX
- Stock Information
- Founded
- FHI 1955
- PTGX 2006
- Country
- FHI United States
- PTGX United States
- Employees
- FHI N/A
- PTGX N/A
- Industry
- FHI Investment Managers
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- FHI Finance
- PTGX Health Care
- Exchange
- FHI Nasdaq
- PTGX Nasdaq
- Market Cap
- FHI 3.4B
- PTGX 3.3B
- IPO Year
- FHI N/A
- PTGX 2016
- Fundamental
- Price
- FHI $46.13
- PTGX $53.00
- Analyst Decision
- FHI Hold
- PTGX Strong Buy
- Analyst Count
- FHI 7
- PTGX 9
- Target Price
- FHI $42.57
- PTGX $67.11
- AVG Volume (30 Days)
- FHI 672.7K
- PTGX 923.4K
- Earning Date
- FHI 07-31-2025
- PTGX 08-05-2025
- Dividend Yield
- FHI 2.95%
- PTGX N/A
- EPS Growth
- FHI 2.09
- PTGX N/A
- EPS
- FHI 3.58
- PTGX 0.86
- Revenue
- FHI $1,659,262,000.00
- PTGX $207,801,000.00
- Revenue This Year
- FHI $5.57
- PTGX N/A
- Revenue Next Year
- FHI $3.48
- PTGX $53.09
- P/E Ratio
- FHI $12.88
- PTGX $61.48
- Revenue Growth
- FHI 2.19
- PTGX N/A
- 52 Week Low
- FHI $31.94
- PTGX $32.50
- 52 Week High
- FHI $46.84
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- FHI 74.57
- PTGX 53.99
- Support Level
- FHI $45.03
- PTGX $49.38
- Resistance Level
- FHI $46.84
- PTGX $51.51
- Average True Range (ATR)
- FHI 0.70
- PTGX 2.02
- MACD
- FHI 0.18
- PTGX -0.39
- Stochastic Oscillator
- FHI 85.45
- PTGX 46.09
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.